AstraZeneca's Fasenra has been cleared for use by the NHS in England as an add-on treatment for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). The final draft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback